spec sheet10 rows
1P-ETH-LAD (1-propionyl-ETH-LAD) is a research lysergamide combining two structural modifications of LSD; the 6-position N-ethyl substitution that defines the highly potent ETH-LAD, together with a propionyl group on the indole nitrogen. Incubation with human serum demonstrates progressive hydrolysis of 1P-ETH-LAD to ETH-LAD, consistent with prodrug behavior analogous to other N1-acyl lysergamides. ETH-LAD itself is a potent 5-HT2A receptor agonist, so the compound is expected to yield a strong, markedly visual LSD-like psychedelic experience. In vitro metabolic studies place it among a family of LSD-based new psychoactive substances whose N-dealkylation and hydroxylation pathways are catalyzed chiefly by CYP1A2 and CYP3A4.
- Strong visual character
- Long, immersive experience
- Classic psychedelic mindset shifts
- Propionyl prodrug of potent ETH-LAD
- Anxiety and body load
- Vasoconstriction
- Insomnia after use
Mechanism
Like other lysergamides, the active molecule works chiefly as an at the receptor, the receptor that drives the classic psychedelic state, with secondary activity at 5-HT2C and . The 1-propionyl group is thought to be cleaved off after dosing to yield ETH-LAD (6-ethyl-6-nor-LSD), so 1P-ETH-LAD is best understood as a delivery form of that parent compound. Because it is an obscure analog, precise potency and receptor numbers are not well characterized.
receptor fingerprint
receptoragonist (via ETH-LAD)
5-HT2C receptoragonist
receptoragonist
Safetyrisks and cautions, not medical advice
This is a poorly studied compound, so exact potency is uncertain and small differences in amount can matter a lot; ETH-LAD in particular is often reported as more anxiety-provoking and body-loaded than LSD. Avoid it with a personal or family history of psychosis or bipolar disorder, and never combine lysergamides with MAOIs or strongly serotonergic drugs (serotonin toxicity), or with lithium or tramadol (seizure reports). Not medical advice.
Subjective profileweighing the evidence above
A research lysergamide with uncertain potency and a rougher edge than LSD; the anxiety and body load are the usual complaints. Not a first psychedelic for anyone, and never worth mixing with MAOIs, lithium or tramadol.
Resources
This entry is here for reference.
Research
- 2017first citedCrystal Structure of an LSD-Bound Human Serotonin Receptor.
- 2022most recentThe use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamine…
- 1.In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures
- 2.Return of the lysergamides. Part III: Analytical characterization of N(6) -ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD).
- 3.Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD).
- 4.The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides.
- 5.Crystal Structure of an LSD-Bound Human Serotonin Receptor.
- 6.Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor.
6 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Is 1P-ETH-LAD the same as ETH-LAD?
It is thought to convert to ETH-LAD in the body, so the effects are expected to be similar, but it is a distinct, less-studied molecule.
Is it stronger than LSD?
ETH-LAD is often described as roughly comparable to LSD in potency but with a more visual and body-heavy character; exact figures for 1P-ETH-LAD are not established.
Can I mix it with an antidepressant?
Combining lysergamides with MAOIs or other strongly serotonergic drugs is dangerous; this is not medical advice and you should be cautious.
Adverse effects
- Anxiety and body load
- Vasoconstriction
- Insomnia after use
Notes and cautions
- Uncertain potency